Minimal Residual Disease Testing Market: A $2.3 Billion Projection by 2027

Comments · 52 Views

The global minimal residual disease testing market in terms of revenue was estimated to be worth $1.2 billion in 2022 and is poised to reach $2.3 billion by 2027, growing at a CAGR of 14.0% from 2022 to 2027.

According to research report the global minimal residual disease testing market is projected to reach $2.3 billion by 2027, growing at a CAGR of 14.0% from 2022. Key factors driving this market expansion include the rising prevalence of cancer and hematological malignancies, increasing government initiatives to raise awareness about cancer, and growing collaborations among stakeholders. Emerging economies like China, Japan, and India present lucrative opportunities for market players.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215386038

Segmentation Insights:

By Technology:
- The polymerase chain reaction (PCR) segment held the largest share in 2021 due to its ease of use, availability, relative sensitivity, and cost-efficiency.

By Application:
- The hematological malignancies segment is expected to register the highest growth rate during the forecast period, primarily driven by the increasing incidence of leukemia and lymphoma, necessitating continuous patient monitoring.

By End-User:
- In 2021, the hospitals and specialty clinics segment accounted for the largest share owing to the availability of advanced diagnostic devices and skilled healthcare professionals.

Regional Analysis:
- North America dominated the MRD testing market, attributed to the growing incidence of hematological malignancies, well-developed healthcare systems, the presence of leading clinical laboratories, and easy access to advanced diagnostic instruments.

Key Players:
Labcorp Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Sysmex Corporation, NeoGenomics Laboratories, Inc., Adaptive Biotechnologies Corporation, ArcherDX, Inc., Asuragen Inc., Arup Laboratories Inc., Bio-Rad Laboratories, Inc., Cergentis B.V., Molecular MD (ICON plc), Invivoscribe, Inc., Mission Bio, Inc., Natera, Inc., Opko Health, Inc., Quest Diagnostics, and Genetron Health, among others.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=215386038

The report provides a comprehensive analysis of the MRD testing market, including market size, growth projections, segmentation insights, regional dynamics, and competitive landscape. It offers valuable insights for companies operating in this space and those seeking to enter or expand their presence in the MRD testing market.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Comments